Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Technical Review: New Releases from Drug Maker Majors Cushion Against Patent Cliff Effects

LONDON, January 16, 2013 /PRNewswire/ --

All companies mentioned in the release below have received technical review as of the close of yesterday's session. These reports are available for free at http://www.stockcall.com/register

For many major drug manufacturers, including Pfizer Inc.(1) (NYSE: PFE) and Merck & Co. Inc.(2) (NYSE: MRK), the so-called "patent cliff" put a major dent in sales and profits. The loss of exclusivity of many blockbuster drugs allowed generics to be made, and major drug companies have been left to compete with generic versions that are, in most cases, cheaper.

One of the historically best-selling drug which went off-patent in November 2011 is Lipitor. The anti-cholesterol drug was Pfizer's golden goose as it earned the company close to $9.6 billion in revenue in 2011. Merck & Co. also suffered from patent loss with some of its blockbuster drugs such as Singulair, Maxalt, Cozaar/Hyzaar fell off the patent cliff. But these companies have learnt to survive. Register with us today and access the technical report in Merck & Co. at

http://www.StockCall.com/MRK011613.pdf

While several brand-name drug companies have come out with their own generic equivalents, sales have still suffered. Successful marketing abroad has also helped to boost sales for select companies; however; numbers are still down from exclusivity highs. Depressed sales for some could be set to rebound though, as companies are succeeding in bringing a slew of exciting, new products to market.

A number of major drug manufacturers are currently focusing their attention on and receiving FDA or European Commission approval, which if granted creates the potential for big returns. Pfizer recently announced that the European Commission gave its approval to expand the company's pneumococcal conjugate vaccine, Prevenar 13 to children and adolescents between the ages of 6 to 17 years. The vaccine is for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by vaccine-type Streptococcus pneumoniae.

Additionally, industry players are developing treatments and diagnostic methods for a number of conditions, including cancer, Pneumonia, cardiovascular diseases and Alzheimer's among others. With a number of these products newly on the market, it will be interesting to see which, if any, become the next big bread winners for major drug manufacturers.  

Footer:

  1. Pfizer Inc. Technical Analysis [ http://www.StockCall.com/PFE011613.pdf ]  
  2. Merck & Co. Inc. Technical Analysis [ http://www.StockCall.com/MRK011613.pdf ]  

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com  

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that...
Organizations today increasingly rely on Application Performance Management (APM) tools like New Relic to respond to end user complaints, and to track system latency and other key application metrics. With this data, users can often confirm if the application is running slowly an...
Racemi is announcing this update to its migration technology that makes the free online migrations to IBM SoftLayer easier than ever by adding a SoftLayer Object Storage image option for enhanced security and compliance.
Software AG helps organizations transform into Digital Enterprises, so they can differentiate from competitors and better engage customers, partners and employees. Using the Software AG Suite, companies can close the gap between business and IT to create digital systems of differ...
In this challenging environment, a combination of automated integration testing and test virtualization can enable test teams to improve software quality and keep up with the rate of change. This white paper helps address these needs by describing the benefits that can be gained ...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE

Breaking Cloud Computing News

NEW YORK, Sept. 30, 2014 /PRNewswire/ -- ARK Investment Management (ARK) is pleased to announce t...